A randomized, double-blind, parallel-group, multicenter Phase 2b study to assess the efficacy and safety of two different doses of vilaprisan (BAY 1002670) versus placebo in women with symptomatic endometriosis
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Vilaprisan (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Acronyms VILLENDO
- Sponsors Bayer; Bayer HealthCare
- 05 Dec 2019 This trial is Prematurely Ended in Bulgaria and Spain, according to European Clinical Trials Database record.
- 14 Feb 2019 Planned End Date changed from 14 Aug 2021 to 17 Aug 2022.
- 23 Jan 2019 This trial has been suspended in Sweden.